Cargando…

Surgery offers survival advantage over radiotherapy in patients who are 80 years and older with Stage I and II NSCLC: A retrospective cohort study of 7,045 patients

OBJECTIVE: Elderly people are less likely than younger patients to undergo curative surgery for early-stage lung cancer because of the greater risk of surgery and postoperative complications. We investigated the relationship between treatment modality and the risk of all-cause and lung cancer-specif...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Qiang, Hu, Sheng, Ye, Jiayue, Su, Lang, Wang, Silin, Zhang, Deyuan, Zhang, Yang, Qiu, Shengyu, Zhu, Lingxiao, Ruan, Liancheng, Wan, Bingen, Zou, Sheng, Zhang, Wenxiong, Yu, Dongliang, Xu, Jianjun, Zhang, Huiliang, Wei, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577077/
https://www.ncbi.nlm.nih.gov/pubmed/36268213
http://dx.doi.org/10.3389/fsurg.2022.1018320
_version_ 1784811676157083648
author Guo, Qiang
Hu, Sheng
Ye, Jiayue
Su, Lang
Wang, Silin
Zhang, Deyuan
Zhang, Yang
Qiu, Shengyu
Zhu, Lingxiao
Ruan, Liancheng
Wan, Bingen
Zou, Sheng
Zhang, Wenxiong
Yu, Dongliang
Xu, Jianjun
Zhang, Huiliang
Wei, Yiping
author_facet Guo, Qiang
Hu, Sheng
Ye, Jiayue
Su, Lang
Wang, Silin
Zhang, Deyuan
Zhang, Yang
Qiu, Shengyu
Zhu, Lingxiao
Ruan, Liancheng
Wan, Bingen
Zou, Sheng
Zhang, Wenxiong
Yu, Dongliang
Xu, Jianjun
Zhang, Huiliang
Wei, Yiping
author_sort Guo, Qiang
collection PubMed
description OBJECTIVE: Elderly people are less likely than younger patients to undergo curative surgery for early-stage lung cancer because of the greater risk of surgery and postoperative complications. We investigated the relationship between treatment modality and the risk of all-cause and lung cancer-specific mortality to compare the efficacy of surgical treatment with radiotherapy in patients with stage I and II non-small cell lung cancer (NSCLC) who were ≥80 years old. METHODS: We extracted data from the most recent Surveillance, Epidemiology, and End Results 9 registry study database (2010–2017). We mainly selected patients with stage I and II NSCLC who were ≥80 years old, and after screening, 7,045 cases were selected for our study. We used univariate analysis, stratified analysis, and multiple regression equation analysis to examine all-cause mortality and lung cancer-specific mortality in different treatment modalities. The overall and stratified populations' survival curves were plotted using the Kaplan–Meier method. The competing risk regression method of Fine and Gray was used to estimate mortality specific to lung cancer. RESULTS: In the fully adjusted model, all-cause mortality was 1.97 times higher in the radiotherapy-only group (hazard ration (HR) = 1.97, 95% confidence interval (CI) = 1.81–2.14, p < 0.0001) than in the surgery-only group. The lung cancer-specific mortality rate was 1.22 times higher in the radiotherapy-only group (HR = 1.22, 95% CI = 1.13–1.32, p < 0.0001) than in the surgery-only group. The median overall survival (OS) in the surgery-only, radiation therapy-only, surgery plus radiation therapy, and no-treatment groups were 58 months, 31 months, 36 months, and 10 months, respectively. Median lung cancer-specific survival was 61 months, 32 months, 38 months, and 11 months, respectively. The surgery-only group had the highest 1-year OS (0.8679,95% CI = 0.8537–0.8824) and 5-year OS (0.4873, 95% CI = 0.4632–0.5126). CONCLUSIONS: Surgery had a higher overall and lung cancer-specific survival rate than radiotherapy and no treatment in the elderly early-stage NSCLC population. For patients with stage I and stage II NSCLC at advanced ages, surgical treatment might have a greater potential survival benefit.
format Online
Article
Text
id pubmed-9577077
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95770772022-10-19 Surgery offers survival advantage over radiotherapy in patients who are 80 years and older with Stage I and II NSCLC: A retrospective cohort study of 7,045 patients Guo, Qiang Hu, Sheng Ye, Jiayue Su, Lang Wang, Silin Zhang, Deyuan Zhang, Yang Qiu, Shengyu Zhu, Lingxiao Ruan, Liancheng Wan, Bingen Zou, Sheng Zhang, Wenxiong Yu, Dongliang Xu, Jianjun Zhang, Huiliang Wei, Yiping Front Surg Surgery OBJECTIVE: Elderly people are less likely than younger patients to undergo curative surgery for early-stage lung cancer because of the greater risk of surgery and postoperative complications. We investigated the relationship between treatment modality and the risk of all-cause and lung cancer-specific mortality to compare the efficacy of surgical treatment with radiotherapy in patients with stage I and II non-small cell lung cancer (NSCLC) who were ≥80 years old. METHODS: We extracted data from the most recent Surveillance, Epidemiology, and End Results 9 registry study database (2010–2017). We mainly selected patients with stage I and II NSCLC who were ≥80 years old, and after screening, 7,045 cases were selected for our study. We used univariate analysis, stratified analysis, and multiple regression equation analysis to examine all-cause mortality and lung cancer-specific mortality in different treatment modalities. The overall and stratified populations' survival curves were plotted using the Kaplan–Meier method. The competing risk regression method of Fine and Gray was used to estimate mortality specific to lung cancer. RESULTS: In the fully adjusted model, all-cause mortality was 1.97 times higher in the radiotherapy-only group (hazard ration (HR) = 1.97, 95% confidence interval (CI) = 1.81–2.14, p < 0.0001) than in the surgery-only group. The lung cancer-specific mortality rate was 1.22 times higher in the radiotherapy-only group (HR = 1.22, 95% CI = 1.13–1.32, p < 0.0001) than in the surgery-only group. The median overall survival (OS) in the surgery-only, radiation therapy-only, surgery plus radiation therapy, and no-treatment groups were 58 months, 31 months, 36 months, and 10 months, respectively. Median lung cancer-specific survival was 61 months, 32 months, 38 months, and 11 months, respectively. The surgery-only group had the highest 1-year OS (0.8679,95% CI = 0.8537–0.8824) and 5-year OS (0.4873, 95% CI = 0.4632–0.5126). CONCLUSIONS: Surgery had a higher overall and lung cancer-specific survival rate than radiotherapy and no treatment in the elderly early-stage NSCLC population. For patients with stage I and stage II NSCLC at advanced ages, surgical treatment might have a greater potential survival benefit. Frontiers Media S.A. 2022-10-04 /pmc/articles/PMC9577077/ /pubmed/36268213 http://dx.doi.org/10.3389/fsurg.2022.1018320 Text en © 2022 Guo, Hu, Ye, Su, Wang, Zhang, Zhang, Qiu, Zhu, Ruan, Wan, Zou, Zhang, Yu, Xu, Zhang and Wei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Surgery
Guo, Qiang
Hu, Sheng
Ye, Jiayue
Su, Lang
Wang, Silin
Zhang, Deyuan
Zhang, Yang
Qiu, Shengyu
Zhu, Lingxiao
Ruan, Liancheng
Wan, Bingen
Zou, Sheng
Zhang, Wenxiong
Yu, Dongliang
Xu, Jianjun
Zhang, Huiliang
Wei, Yiping
Surgery offers survival advantage over radiotherapy in patients who are 80 years and older with Stage I and II NSCLC: A retrospective cohort study of 7,045 patients
title Surgery offers survival advantage over radiotherapy in patients who are 80 years and older with Stage I and II NSCLC: A retrospective cohort study of 7,045 patients
title_full Surgery offers survival advantage over radiotherapy in patients who are 80 years and older with Stage I and II NSCLC: A retrospective cohort study of 7,045 patients
title_fullStr Surgery offers survival advantage over radiotherapy in patients who are 80 years and older with Stage I and II NSCLC: A retrospective cohort study of 7,045 patients
title_full_unstemmed Surgery offers survival advantage over radiotherapy in patients who are 80 years and older with Stage I and II NSCLC: A retrospective cohort study of 7,045 patients
title_short Surgery offers survival advantage over radiotherapy in patients who are 80 years and older with Stage I and II NSCLC: A retrospective cohort study of 7,045 patients
title_sort surgery offers survival advantage over radiotherapy in patients who are 80 years and older with stage i and ii nsclc: a retrospective cohort study of 7,045 patients
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577077/
https://www.ncbi.nlm.nih.gov/pubmed/36268213
http://dx.doi.org/10.3389/fsurg.2022.1018320
work_keys_str_mv AT guoqiang surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT husheng surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT yejiayue surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT sulang surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT wangsilin surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT zhangdeyuan surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT zhangyang surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT qiushengyu surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT zhulingxiao surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT ruanliancheng surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT wanbingen surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT zousheng surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT zhangwenxiong surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT yudongliang surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT xujianjun surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT zhanghuiliang surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients
AT weiyiping surgeryofferssurvivaladvantageoverradiotherapyinpatientswhoare80yearsandolderwithstageiandiinsclcaretrospectivecohortstudyof7045patients